The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be …

Langerhans Cell Histiocytosis (LCH)Juvenile Xanthogranuloma (JXG)Rosai-Dorfman Disease (RDD)+1 more

~Estimated

~$10 – $5,625

Children's Hospital Medical Center, CincinnatiNCT06153173

Phase 2

A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.

This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorder…

Langerhan's Cell HistiocytosisJuvenile XanthogranulomaErdheim-Chester Disease+4 more

~Estimated

~$10 – $7,500

Carl AllenNCT04079179